Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

NIH's Zika Vaccine Faces Funding Challenge After Skipping Industry Partnership

Executive Summary

Agency wanted to move fast, but is now scrambling to pay for Phases I and II trials.


Related Content

Zika Vaccine Trials Could Test Multiple Candidates Vs. Common Control Group
Public Health Funding Faces Grim Prospects Before, After Election
Pediatric Rare Disease Voucher Program Faces Expiration
Playing the Long Game, Partnerships Required For Emerging Infectious Diseases
Feds Closer To Dx Distinguishing Zika From Dengue As HHS Tries To Plug Funding Gap
GSK/NIH 'SAM' Strategy May Reap Benefits Beyond Zika
Sanofi Teams With US Military On Zika, But Not For The Profits
Robbing Ebola To Pay For Zika: Playing With Fire?


Related Companies